Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
141
resultados
Última actualización
09/08/2025 [07:11:00]
Resultados 100 a 125 de 141
Resumen de: WO2025137284A2
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.
Resumen de: US2025205273A1
The present invention relates to a composition comprising at least chitosan and xanthohumolone, to a process for preparing same and to the uses thereof. More particularly, the invention relates to a composition comprising at least chitosan and xanthohumolone for use as an antiviral composition, in particular in the treatment or prevention of COVID-19.
Resumen de: US2025207140A1
Provided herein, inter alia, are compositions comprising nucleic acid compounds and methods of using the compositions for the prevention and treatment of respiratory diseases, including SARS-CoV-2 infections.
Resumen de: AU2023326053A1
Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological sample from the subject. Also disclosed herein are methods for treating a subject identified as having a high likelihood of suffering from NP ASC and treating the subject by modulating the level or activity of an NPASC therapeutic target identified herein.
Resumen de: GB2636672A
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Resumen de: ZA202401786B
Disclosed is a method for treating a subject that has previously been infected with SARS-CoV-2 and exhibiting at least one Post COVID- 19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.
Resumen de: KR20220166497A
The present invention relates to a composition containing a Schisandra chinensis extract as an active ingredient for preventing or treating coronavirus infection-19 (COVID-19). The Schisandra chinensis extract according to the present invention was confirmed to suppress invasion of inflammatory cells in alveoli, to reduce expression of ACE2, which is an RBD receptor, and p-STAT3 and IL-6, which are inflammation-related factors, to suppress phosphorylation of JNK, ERK, p38, IκB, and NFκB in an inflammatory signal transduction pathway, and to increase the expression of Nrf2 and NQO-1, which are antioxidant factors, in a respiratory disease mouse induced by a receptor-binding domain (RBD), which is a protein constituting a spike of SARS-CoV-2. Accordingly, it can be usefully used in related industries.
Resumen de: WO2025127420A1
The present invention relates to engineered human antibodies having neutralizing activity against human coronavirus and use thereof. The novel human antibodies against coronavirus, of the present invention, specifically bind to SARS-CoV-1, SARS-CoV-2, or a variant thereof, exhibit neutralizing activity against SARS-CoV-1, SARS-CoV-2, or a variant thereof, and have cross-reactivity, and thus can be used for the prevention or treatment of coronavirus infection. In addition, the antibodies and fragments having immunological activities thereof can be used to rapidly detect various types of coronaviruses, and thus can be used for the immunodiagnosis of human coronaviruses, particularly SARS-CoV-2 with high infectivity, and variants thereof.
Resumen de: WO2025127075A1
The problem addressed is to provide surface-modified iron oxide nanoparticles for use in a vaccine exhibiting an infection preventive effect on SARS-CoV-2. The problem can be solved by surface-modified iron oxide nanoparticles comprising SARS-CoV-2 spike protein and iron oxide nanoparticles, where the spike protein of SARS-CoV-2 is bound to the surface of the iron oxide nanoparticles.
Resumen de: US2025201406A1
Method for predicting severity of COVID-19 disease resulting from infection with SARS-COV-2 (severe acute respiratory syndrome coronavirus 2). The method uses a high dimensional approach to construct a comprehensive metabolic landscape of immune cells participating in the anti-viral response against SARS-CoV-2. Also encompassed within the invention are novel immune cell subsets exhibiting metabolic dysfunction that could serve as predictive biomarkers for COVID-19 severity or as targets for therapeutic interventions in COVID-19 disease.
Resumen de: WO2025125852A1
An oral vaccine for COVID-19 is disclosed. The oral vaccine for COVID-19 includes a delivery platform including Arthrospira platensis with a plurality of host genomes and a plurality of COVID-19 antigen delivery vectors coupled to the plurality of host genomes. Each respective host genome of the plurality of host genomes includes a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 1. Each COVID-19 antigen delivery vector of the plurality of COVID- 19 antigen delivery vectors has a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 2. Each respective COVID-19 antigen delivery vector of the plurality of COVID-19 antigen delivery vectors includes at least one antigen of COVID-19 with a weight ratio of the delivery platform to the at least one antigen of COVID-19in a range of 1: 10-3 to 1: 2.5 × 10-3 (delivery platform: at least one antigen of COVID-19).
Resumen de: US2025195639A1
In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.
Resumen de: WO2025127420A1
The present invention relates to engineered human antibodies having neutralizing activity against human coronavirus and use thereof. The novel human antibodies against coronavirus, of the present invention, specifically bind to SARS-CoV-1, SARS-CoV-2, or a variant thereof, exhibit neutralizing activity against SARS-CoV-1, SARS-CoV-2, or a variant thereof, and have cross-reactivity, and thus can be used for the prevention or treatment of coronavirus infection. In addition, the antibodies and fragments having immunological activities thereof can be used to rapidly detect various types of coronaviruses, and thus can be used for the immunodiagnosis of human coronaviruses, particularly SARS-CoV-2 with high infectivity, and variants thereof.
Resumen de: US2025195557A1
An objective of the present invention is to provide a nonpharmaceutical anti-human coronavirus composition that prevents human coronavirus infections, the onset of the infections, or aggravation of symptoms of the infections. The anti-human coronavirus composition according to the present invention includes an exopolysaccharide produced by a lactic acid bacterium in genus Lactobacillus as an active component. The lactic acid bacterium in the genus Lactobacillus may belong to a Lactobacillus delbrueckii species. The lactic acid bacterium in the genus Lactobacillus may specifically be Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).
Resumen de: US2025195464A1
Provided herein are Alotaketal compounds and derivatives thereof that have antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (1), (2) and (3), for use as antiviral agents in the treatment or prevention of coronavirus infection. Methods for using the compounds in the treatment or prophylaxis of a coronavirus infection are provided. In particular, the coronavirus infection may selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus-1 (SARS-C0V-1) infection; SARS coronavirus-2 (SARS-C0V-2) infection; and Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) infection. More specifically, the coronavirus infection may be a human coronavirus 229E (HC0V-229E) infection.
Resumen de: AU2023378779A1
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
Resumen de: WO2025128200A1
Disclosed is a method of treating lung injury in a patient comprising providing a therapeutically effective amount of a pharmaceutical agent that enhances peroxisome biogenesis to a patient. The method includes increasing the number of peroxisomes in alveolar macrophages, decreasing peroxisome degradation, and improving peroxisome function in alveolar macrophages. Increasing the number and function of peroxisomes in alveolar macrophages promotes healing of lung injury and regeneration of alveolar epithelial. The lung injury may be due to infection, including viral infection, such as SARS-CoV-2 infection or influenza infection. The lung injury may also be due to exposure to caustic substances, tobacco smoke, asbestos, or fine particulate matter.
Resumen de: EP4570816A1
The present invention relates to a specific inhibitor of IL-6 trans-signaling, the protein sgp130Fc, for use in the treatment or prevention of a disease caused by coronavirus infection in a subject, preferably caused by SARS-CoV-2.
Resumen de: ES3027732A1
In vitro use of KLRB1 expression levels in previously isolated samples of nasopharyngeal mucosa as a biomarker to predict and/or prognose the evolution of patients with COVID-19. (Machine-translation by Google Translate, not legally binding)
Resumen de: KR20230064339A
The present invention relates to a primer set for ring-mediated isothermal amplification to detect the 2019 novel coronavirus, a composition for detecting the 2019 novel coronavirus containing the same, a kit for detecting the 2019 novel coronavirus containing the same, and a method for detecting the 2019 novel coronavirus using the same. The primer set for ring-mediated isothermal amplification for detecting the 2019 novel coronavirus according to the present invention detects the coronavirus specifically and with high sensitivity (10-3), and can be usefully used for the detection of the coronavirus economically and easily.
Resumen de: WO2025121804A1
Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting porcine epidemic diarrhea virus, a one-step diagnostic kit for porcine epidemic diarrhea, and a one-step diagnostic method for porcine epidemic diarrhea. Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting SARS-CoV-2 nucleoprotein, a one-step SARS-CoV-2 diagnostic kit, and a one-step SARS-CoV-2 diagnostic method.
Resumen de: US2025188102A1
A triazine compound, an intermediate thereof, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a triazine derivative as represented by formula (I′) or a pharmaceutically acceptable salt thereof. On the basis of retaining the effectiveness against SARS-CoV-2, the compound significantly prolongs the half-life period, reduces the dosage requirement, reduces side effects, expands the range of therapeutic window, and has very good prospects when used for manufacturing a drug for treating diseases related to coronavirus infections.
Resumen de: WO2025122814A1
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
Resumen de: KR20250085005A
펩타이드, 항체 또는 이의 항원 결합 단편, 핵산, 재조합 발현 벡터, 세포, SARS-CoV-2 핵단백질 검출용 물질, 원스텝 SARS-CoV-2 진단 키트 및 원스텝 SARS-CoV-2 진단 방법이 개시된다.
Nº publicación: US2025186443A1 12/06/2025
Solicitante:
PRIDGEN WILLIAM LANGLEY [US]
PRIDGEN William Langley
Resumen de: US2025186443A1
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
BOPI
Sede Electrónica
